Semmax Financial Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Semmax Financial Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,849	Closed	-$18.4K	–	437
2025 Q1	$18.4K	Hold	1,849	–	–	0.01%	206
2024 Q4	$16.3K	Hold	1,849	–	–	﹤0.01%	198
2024 Q3	$14.5K	Hold	1,849	–	–	﹤0.01%	198
2024 Q2	$14.6K	Hold	1,849	–	–	﹤0.01%	214
2024 Q1	$10.4K	Hold	1,849	–	–	﹤0.01%	206
2023 Q4	$9.84K	Hold	1,849	–	–	﹤0.01%	213
2023 Q3	$9.52K	Buy	+1,849	New	+$13.3K	﹤0.01%	194
2022 Q4	$18K	Hold	1,849	–	–	0.01%	155
2022 Q3	$22K	Hold	1,849	–	–	0.01%	140
2022 Q2	$27K	Buy	1,849 +150	+9%	+$1.55K	0.01%	133
2022 Q1	$28K	Buy	1,699 +1,352	+390%	+$21.7K	0.01%	152
2021 Q4	$5K	Hold	347	–	–	﹤0.01%	208
2021 Q3	$5K	Buy	+347	New	+$5.47K	﹤0.01%	196

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Semmax Financial Advisors's BCRX Position: Q2 2025 in Review

Semmax Financial Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2025, closing a stake of 1,849 shares — an estimated $18.4K sold.

Semmax Financial Advisors first reported a position in BCRX in Q3 2021 and held it in 13 quarters. The position peaked at $28K in Q1 2022. 294 funds tracked by Wall St. Rank hold BCRX as of Q2 2025.

Semmax Financial Advisors reported no remaining BioCryst Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Semmax Financial Advisors sold 1,849 BioCryst Pharmaceuticals shares in Q2 2025, an estimated $18.4K.
Semmax Financial Advisors first reported a position in BioCryst Pharmaceuticals in Q3 2021 and held it in 13 quarters.
Semmax Financial Advisors's BioCryst Pharmaceuticals position peaked at $28K in Q1 2022.
294 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2025.

Based on Semmax Financial Advisors's 13F filing for Q2 2025, filed 15 Aug 2025.